DrugBiological
MEDI8852 clinical trials
Also written MEDI8852.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
4 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2015 | 2 |
| 2017 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses MEDI8852 is read from its arms, and is right about nine times in ten.
Testing it · 4
- Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat InfluenzaWithdrawnPhase 2MedImmune LLCNCT03903718Written as MEDI8852
- Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Type A Influenza.WithdrawnPhase 2MedImmune LLCNCT03028909Written as MEDI8852
- A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated InfluenzaCompletedPhase 1/2MedImmune LLCNCT02603952Written as MEDI8852
- Phase 1 Placebo-controlled,Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in AdultsCompletedPhase 1MedImmune LLCNCT02350751Written as MEDI8852
Codes
What other systems call MEDI8852 · ClinicalTrials.gg INT000967
- MeSH (NLM) C000627863MEDI8852Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) OZS4TXB9VOMEDI-8852Confirmed FDA, NLM
- NCI Thesaurus C131295Anti-HA Epitope Monoclonal Antibody MEDI8852One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000627863 | MEDI8852 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | OZS4TXB9VO | MEDI-8852 | Confirmed FDA, NLM |
| NCI Thesaurus | C131295 | Anti-HA Epitope Monoclonal Antibody MEDI8852 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.